← All trials
NCT04678154
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 7, 2021
- Primary completion
- Oct 28, 2023
- Completion date
- Mar 30, 2024
- First posted
- Dec 21, 2020
- Last posted
- Jul 2, 2021
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Major Extremity Trauma Research ConsortiumLead sponsor
- Johns Hopkins UniversityOverall official - principal investigator
- Atrium Medical CenterOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.